CYTK
Cytokinetics, Incorporated Healthcare - Biotechnology Investor Relations →
Cytokinetics, Incorporated (CYTK) closed at $78.78 as of 2026-06-19, trading 56.8% above its 200-week moving average of $50.25. The stock moved further from the line this week, up from 40.0% last week. With a 14-week RSI of 71, CYTK is in overbought territory.
Over the past 14 weeks, up-weeks have carried more volume than down-weeks (1.63 buyers-vs-sellers ratio). When trading picks up, it's more often on days the price is rising — buyers are showing more interest than sellers.
Over the past 1107 weeks of data, CYTK has crossed below its 200-week moving average 21 times. On average, these episodes lasted 29 weeks. Historically, investors who bought CYTK at the start of these episodes saw an average one-year return of +36.6%.
With a market cap of $10.7 billion, CYTK is a large-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. The stock trades at -11.8x book value.
Share count has increased 29.6% over three years, indicating dilution.
Over the past 21.2 years, a hypothetical investment of $100 in CYTK would have grown to $267, compared to $952 for the S&P 500. CYTK has returned 4.7% annualized vs 11.2% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: CYTK vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After CYTK Crosses Below the Line?
Across 21 historical episodes, buying CYTK when it crossed below its 200-week moving average produced an average return of +39.6% after 12 months (median +48.0%), compared to +15.0% for the S&P 500 over the same periods. 67% of those episodes were profitable after one year. After 24 months, the average return was +80.7% vs +31.2% for the index.
Each line shows $100 invested at the moment CYTK crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. CYTK currently has negative free cash flow, so price-based dislocation levels are not available. The score still tracks yield deviation from baseline.
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from CYTK's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
CYTK has crossed below its 200-week MA 21 times with an average 1-year return of +36.6% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Apr 2005 | Oct 2009 | 235 | 72.7% | +9.9% | +96.3% |
| Oct 2009 | Jun 2013 | 191 | 73.1% | -43.1% | +187.3% |
| Aug 2013 | Aug 2013 | 1 | 0.2% | -55.1% | +682.3% |
| Sep 2013 | Jan 2014 | 18 | 36.3% | -55.5% | +820.3% |
| Jan 2014 | Feb 2014 | 2 | 10.7% | -10.5% | +854.9% |
| Apr 2014 | Dec 2014 | 36 | 55.7% | +58.0% | +1616.3% |
| Feb 2015 | Feb 2015 | 1 | 1.9% | +8.5% | +1136.7% |
| Apr 2015 | Jun 2015 | 5 | 12.4% | +44.1% | +1294.3% |
| Jun 2015 | Jul 2015 | 2 | 5.0% | +52.1% | +1140.6% |
| Jul 2015 | Aug 2015 | 1 | 0.3% | +74.0% | +1132.9% |
| Feb 2016 | Mar 2016 | 4 | 7.5% | +84.2% | +1156.5% |
| Nov 2017 | Jan 2018 | 7 | 14.2% | -4.3% | +936.6% |
| Jan 2018 | Jul 2018 | 22 | 20.5% | -18.3% | +810.8% |
| Jul 2018 | May 2019 | 42 | 36.5% | +26.6% | +795.2% |
| Jun 2019 | Jun 2019 | 1 | 1.4% | +124.1% | +725.8% |
| Nov 2019 | Dec 2019 | 5 | 18.0% | +106.6% | +860.7% |
| Mar 2020 | Mar 2020 | 1 | 8.0% | +160.3% | +724.9% |
| Sep 2023 | Oct 2023 | 2 | 3.4% | +77.7% | +167.4% |
| Feb 2025 | Feb 2025 | 1 | 2.3% | +45.8% | +84.2% |
| Mar 2025 | Mar 2025 | 1 | 1.7% | +39.1% | +81.4% |
| Mar 2025 | Sep 2025 | 23 | 32.2% | +44.7% | +82.4% |
| Average | 29 | — | +36.6% | — |
Frequently Asked Questions
Is CYTK below its 200-week moving average?
No. Cytokinetics, Incorporated (CYTK) is currently 56.8% above its 200-week moving average of $50.25. It would need to fall to $50.25 to cross below the line.
What is CYTK's 200-week moving average price?
Cytokinetics, Incorporated's 200-week moving average is $50.25 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when CYTK drops below its 200-week moving average?
CYTK has crossed below its 200-week moving average 21 times in our data. On average, buying at that moment produced a one-year return of +36.6%. These dips have historically been decent entry points. These episodes lasted 29 weeks on average.
Is CYTK a good value right now?
Here's what our data says about CYTK as of 2026-06-19: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 71 (overbought). Free cash flow is currently negative. Price-to-book is -11.8x. This is not a buy or sell recommendation — always do your own research.
How does CYTK compare to the S&P 500?
Over the past 21.2 years, $100 invested in CYTK would have grown to $267, compared to $952 for the S&P 500. That's 4.7% annualized vs 11.2% for the index. CYTK has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19